BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 9060563)

  • 1. Timing and magnitude of decline in alpha-fetoprotein levels in treated children with unresectable or metastatic hepatoblastoma are predictors of outcome: a report from the Children's Cancer Group.
    Van Tornout JM; Buckley JD; Quinn JJ; Feusner JH; Krailo MD; King DR; Hammond GD; Ortega JA
    J Clin Oncol; 1997 Mar; 15(3):1190-7. PubMed ID: 9060563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic implications of serum alpha-fetoprotein response during treatment of hepatoblastoma.
    Koh KN; Park M; Kim BE; Bae KW; Kim KM; Im HJ; Seo JJ
    Pediatr Blood Cancer; 2011 Oct; 57(4):554-60. PubMed ID: 21370433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach--results of the first prospective study of the International Society of Pediatric Oncology.
    Pritchard J; Brown J; Shafford E; Perilongo G; Brock P; Dicks-Mireaux C; Keeling J; Phillips A; Vos A; Plaschkes J
    J Clin Oncol; 2000 Nov; 18(22):3819-28. PubMed ID: 11078495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretransplant trends in α-fetoprotein levels as a predictor of recurrence after living donor liver transplantation for unresectable hepatoblastoma: A single-institution experience.
    Isono K; Ohya Y; Lee KJ; Hashimoto S; Kadohisa M; Sakisaka M; Uto K; Hayashida S; Yamamoto H; Yamamoto H; Sugawara Y; Inomata Y
    Pediatr Transplant; 2018 Aug; 22(5):e13221. PubMed ID: 29761829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival after liver transplantation for hepatoblastoma: a 2-center experience.
    Browne M; Sher D; Grant D; Deluca E; Alonso E; Whitington PF; Superina RA
    J Pediatr Surg; 2008 Nov; 43(11):1973-81. PubMed ID: 18970927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upfront window vincristine/irinotecan treatment of high-risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 study committee.
    Katzenstein HM; Furman WL; Malogolowkin MH; Krailo MD; McCarville MB; Towbin AJ; Tiao GM; Finegold MJ; Ranganathan S; Dunn SP; Langham MR; McGahren ED; Rodriguez-Galindo C; Meyers RL
    Cancer; 2017 Jun; 123(12):2360-2367. PubMed ID: 28211941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective treatment of unresectable or metastatic hepatoblastoma with cisplatin and continuous infusion doxorubicin chemotherapy: a report from the Childrens Cancer Study Group.
    Ortega JA; Krailo MD; Haas JE; King DR; Ablin AR; Quinn JJ; Feusner J; Campbell JR; Lloyd DA; Cherlow J
    J Clin Oncol; 1991 Dec; 9(12):2167-76. PubMed ID: 1720452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can we predict the prognosis of resectable hepatoblastoma from serum alpha-fetoprotein response during preoperative chemotherapy?
    Fukuzawa H; Urushihara N; Fukumoto K; Mitsunaga M; Watanabe K; Aoba T; Yamoto S; Miyake H; Hasegawa S
    Pediatr Surg Int; 2012 Sep; 28(9):887-91. PubMed ID: 22948667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete resection before development of drug resistance is essential for survival from advanced hepatoblastoma--a report from the German Cooperative Pediatric Liver Tumor Study HB-89.
    von Schweinitz D; Hecker H; Harms D; Bode U; Weinel P; Bürger D; Erttmann R; Mildenberger H
    J Pediatr Surg; 1995 Jun; 30(6):845-52. PubMed ID: 7545228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of postoperative chemotherapy on the serum alpha-fetoprotein level in hepatoblastoma.
    Kubota M; Yagi M; Kanada S; Yamazaki S; Tanaka S; Asami K; Ogawa A; Watanabe A; Iwabuchi H; Kaneko M; Saida Y
    J Pediatr Surg; 2004 Dec; 39(12):1775-8. PubMed ID: 15616926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carboplatin-epirubicin regimen for the treatment of hepatoblastoma.
    Blouin P; Brugières L; Tabone MD; Leverger G; Rubie H; Branchereau S; De Kraker J
    Pediatr Blood Cancer; 2004 Feb; 42(2):149-54. PubMed ID: 14752879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Differentiated treatment protocols for high- and standard-risk hepatoblastoma--an interim report of the German Liver Tumor Study HB99].
    Häberle B; Bode U; von Schweinitz D
    Klin Padiatr; 2003; 215(3):159-65. PubMed ID: 12778356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Features predicting unresectability in hepatoblastoma.
    D'Antiga L; Vallortigara F; Cillo U; Talenti E; Rugge M; Zancan L; Dall'Igna P; De Salvo GL; Perilongo G
    Cancer; 2007 Sep; 110(5):1050-8. PubMed ID: 17661341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid decrease of serum alpha-fetoprotein and tumor volume predicts outcome in children with hepatoblastoma treated with neoadjuvant chemotherapy.
    Nguyen R; McCarville MB; Sykes A; Mao S; Wu J; Langham MR; Furman WL
    Int J Clin Oncol; 2018 Oct; 23(5):900-907. PubMed ID: 29744604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Results of the HB-89 Study in treatment of malignant epithelial liver tumors in childhood and concept of a new HB-94 protocol].
    von Schweinitz D; Bürger D; Bode U; Weinel P; Erttmann R; Hecker H; Mildenberger H
    Klin Padiatr; 1994; 206(4):282-8. PubMed ID: 7526028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of alpha-fetoprotein secreting hepatoblastoma by response of serum alpha-fetoprotein levels: a new concept.
    Sayar D; Yaniv I; Goshen Y; Cohen IJ
    Pediatr Hematol Oncol; 2001 Dec; 18(8):509-18. PubMed ID: 11764100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib and bevacizumab for recurrent metastatic hepatoblastoma: stable radiographic disease with decreased AFP.
    Marsh AM; Lo L; Cohen RA; Feusner JH
    Pediatr Blood Cancer; 2012 Nov; 59(5):939-40. PubMed ID: 22492703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum α-fetoprotein concentration in extremely low-birthweight infants.
    Maruyama K
    Pediatr Int; 2017 Feb; 59(2):159-162. PubMed ID: 27400853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma--a phase II trial of the childhood liver tumour strategy group (SIOPEL).
    Zsíros J; Brugières L; Brock P; Roebuck D; Maibach R; Child M; Morland B; Casanova M; Pariente D; Paris C; de Camargo B; Ronghe M; Zimmermann A; Plaschkes J; Czauderna P; Perilongo G
    Eur J Cancer; 2012 Dec; 48(18):3456-64. PubMed ID: 22835780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of unresectable and metastatic hepatoblastoma: a pediatric oncology group phase II study.
    Katzenstein HM; London WB; Douglass EC; Reynolds M; Plaschkes J; Finegold MJ; Bowman LC
    J Clin Oncol; 2002 Aug; 20(16):3438-44. PubMed ID: 12177104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.